Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 7.0, indicating strong short-term liquidity coverage. The company holds $754,323 in cash and equivalents against total assets of $5,789,536 and total liabilities of $827,310. Despite this liquidity buffer, the firm reported an operating cash flow of -$1,773,510 in Q1 2026, reflecting significant cash burn typical of pre-revenue clinical development stages. The market capitalization stands at $44,523,357, implying a price-to-book ratio of 8.97, which suggests the market is pricing in future optionality rather than current asset value.

Profitability metrics are negative, with a return on equity of -19.97% and a return on assets of -17.12% for the latest period. The company reported a net loss of $990,947 in Q1 2026. As a pre-revenue entity, Telomir does not generate operating income, and its financial performance is driven entirely by R&D expenditures and general administrative costs. The absence of revenue results in undefined margin metrics, and the company’s economic model relies on successful clinical outcomes to transition from cash burn to potential commercialization.

The company does not disclose segmented revenue or geographic breakdowns, consistent with its status as a single-product-candidate developer in the pre-commercial phase. All activities are consolidated under the primary pharmaceutical development unit. There is no concentration risk from customer or regional revenue sources, as no sales are currently recorded. The operational focus is entirely on advancing product candidates through clinical trials and regulatory pathways.

Growth trajectory is characterized by zero revenue generation, with the last actual revenue reported as $0.00. The company’s historical financials show consistent net losses, with the most recent quarterly net income at -$990,947. Analyst estimates project a mean EPS of -$0.28, compared to the last actual EPS of -$0.33, indicating a slight expected improvement in per-share loss metrics, though absolute losses remain significant. The share count remains stable at 34,380,971 basic and diluted shares outstanding.

Risk assessment highlights high liquidity risk due to the substantial cash burn rate and medium dilution risk from potential equity offerings. Key flags include filings referencing going-concern or substantial-doubt language, and source documents mentioning dilution or offering risk. The company’s reliance on external financing to fund operations creates vulnerability to market conditions and investor sentiment. The absence of debt mitigates interest rate risk but increases equity dilution pressure as cash reserves deplete.

Recent events include a significant price decline, with the stock trading at $0.9124, below the $1.00 minimum bid threshold for continued listing on US exchanges. This triggers high-severity listing deficiency alerts, posing an immediate threat to exchange status. Filing observations note partial coverage with backfilled cash data, and forward-looking statements emphasize risks related to regulatory approval, clinical trial progress, and the need for additional financing. The company’s ESG score is 11.16, with low governance and environment pillar scores, reflecting typical early-stage biotech profiles.